Conference Day One
7:25 am Check In & Morning Coffee
8:25 am Chair’s Opening Remarks
Spotlighting the Latest Case Studies Detailing the Successes of US & Global Programs
8:30 am Panel Discussion: Global Trends Within Expanded Access & Its Evolvement For All Stakeholders
Synopsis
- Role of US Expanded Access vs. outside-US
- Recent regulatory trends ex-US
- How emerging markets are increasingly coming into play?
- Addressing the downstream impact on companies' reimbursement status in particular countries
9:00 am Facilitating Treatment Access for Patients Across the Globe
Synopsis
• Delving into the geographic reach of the program
• Long-term commitment to patients
• Creation of a sustainable treatment environment, including market access and patient advocacy
9:30 am Taking it Global: Strategically Designing Expanded Access Programs to Balance the Benefits Vs. Risks
Synopsis
- Epanded Access Program: The evolving regulatory landscape
- Quality Risks: Safety reporting and other GxP considerations
- Navigating Local/regional regulatory requirements
10:00 am Cracking the Code to Post-Trial Access
Synopsis
- Key ways in which post-trial access differs from an extension study
- Regulatory considerations for post-trial access
- Opportunities for data collection
10:30 am Speed Networking Break
Synopsis
This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the EAP field and establish meaningful business relationships
11:30 am Operationalizing an EAP for Pediatric Cancer Patients
Synopsis
• Sharing successes from a small company taking a program global for an ultra-rare disease
• Maximizing vendor partnership
• Strengthening cross-functional relationships
12:00 pm A Small Pharma Approach to Global Access: Case Study in Cohort Programs
Synopsis
• Developing an OUS strategy as a company without a global presence
• Aligning internal stakeholders on submissions for different countries
• Highlighting the importance of vendor resources involved in cohort programs and the regulatory intel they provide
12:30 pm Roundtable Discussion: Mitigating Timelines in LATAM Regions & Improve Relationships with Physicians in Countries with Less Established Regulations
Synopsis
• Clearly defining what needs to be submitted to the regulatory authorities
• Understanding how to navigate both group and individual patient programs
• What are the necessary labelling and regulatory requirements?
1:00 pm Lunch Break & Networking
2:00 pm What to Consider When Moving Beyond US-Only Expanded Access Programs
Synopsis
- Understanding all strategic and operational considerations (Policy, supply-chain, PV etc.)
- Navigating various regulatory archetypes, including country-specific examples.
- Effective allocation of company resources for a phased-approach towards commercialization.
2:30 pm Roundtable Discussion: Dare to Care. Early Access Excellence Amidst Sanctions
Synopsis
- Delving into factors which drive your company’s approach to running an EAP in Sanctioned Countries
- What kind of due diligence activities will you undertake to compliantly supply medicine into a sanctioned country?
- What are the biggest challenges to running an EAP in these countries?
A Physician’s Perspective: Evaluating the Steps Forward Towards Advancing EAPs by Grasping the Experiences of Patients & Physicians
3:00 pm Bringing Life Saving Therapeutics to Patients & Their Execution
Synopsis
• Overcoming the huge unmet need globally
• Highlighting key successful case studies
• Challenges with engaging physicians and patients and unique solutions to overcome this
3:30 pm Expanded Access Drugs in Care: Bridges Built Upon Compassion, Perseverance & Innovation
Synopsis
• How do physicians become aware of expended access programs?
• How can physicians balance the unmet need with the need to move the field forward?
• Recognition of important regulatory hurdles and ways to overcome them
4:00 pm Afternoon Break & Networking
4:30 pm Panel Discussion: Maximizing the Benefits of an Access Program for All Stakeholders
Synopsis
- What are the challenges for physicians, patients, and pharma and how can we best address these challenges
- Do physicians support data collection without compensation
- How to design a program that meets the needs of all stakeholders
Deep Diving into Effective Methods to Maximize Vendor Selection & Qualification
5:00 pm Ethical Decision-Making for Early Access to Investigational Medicines in Rare Disease
Synopsis
- Defining guiding principles
- Determining the key stakeholders
- Considerations for a decision-making framework
5:30 pm Roundtable Discussion: Bridging the Gap Between Industry & Vendors
Synopsis
• Working together to build strong collaborative relationships between vendors and pharma
• What are key regulatory considerations that vendors must address to be selected?
• How does a vendor’s commitment to a patient-centric approach influence its chances of being selected?